|Assessment process complete
|For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR.
|Full pharmacoeconomic assessment commissioned by HSE
|NCPE assessment completed
We do not recommend the reimbursement of gefitinib for first line therapy on the High Tech Drug Scheme. However, it may be considered for second line therapy.